Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Pyrene-4,5-dione REF: 3B-P3004CAS: 6217-22-7 | >98.0%(GC) | 217.00 € | Fri 07 Feb 25 | |
PYRENE-4,5-QUINONE REF: IN-DA00EIJXCAS: 6217-22-7 | 95% | To inquire | Fri 14 Feb 25 | |
Pyrene-4,5-dione REF: 54-OR85319CAS: 6217-22-7 | 97% | 244.00 €~553.00 € | Tue 18 Feb 25 | |
Pyrene-4,5-dione REF: 10-F612593CAS: 6217-22-7 | 95% | 102.00 €~913.00 € | Tue 18 Feb 25 | |
PYRENE-4,5-QUINONE REF: TR-P841323CAS: 6217-22-7 | - - - | 91.00 €~260.00 € | Thu 27 Mar 25 | |
Pyrene-4,5-dione REF: 3D-GAA21722CAS: 6217-22-7 | Min. 95% | - - - | Discontinued product |
Pyrene-4,5-dione
CAS:6217-22-7
Formula:
C16H8O2
Purity:
>98.0%(GC)
Color and Shape:
Light yellow to Yellow to Orange powder to crystal
Molecular weight:
232.24
Ref: 3B-P3004
1g | 217.00 € |
Estimated delivery in United States, on Friday 7 Feb 2025
PYRENE-4,5-QUINONE
CAS:6217-22-7
Formula:
C16H8O2
Purity:
95%
Color and Shape:
Solid
Molecular weight:
232.2335
Ref: IN-DA00EIJX
1g | 238.00 € | ||
5g | To inquire | ||
100mg | 109.00 € | ||
250mg | 130.00 € |
Estimated delivery in United States, on Friday 14 Feb 2025
Ref: 10-F612593
1g | 307.00 € | ||
5g | 913.00 € | ||
100mg | 102.00 € | ||
250mg | 148.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
PYRENE-4,5-QUINONE
Controlled ProductCAS:6217-22-7
Applications PYRENE-4,5-QUINONE (cas# 6217-22-7) is a useful research chemical.
Formula:
C16H8O2
Color and Shape:
Neat
Molecular weight:
232.233
Ref: TR-P841323
5mg | 129.00 € | ||
25mg | 260.00 € | ||
2500µg | 91.00 € |
Estimated delivery in United States, on Thursday 27 Mar 2025
Pyrene-4,5-dione
CAS:6217-22-7
Pyrene-4,5-dione is a coordination complex that has been shown to be a potent inhibitor of …
Formula:
C16H8O2
Purity:
Min. 95%
Molecular weight:
232.24 g/mol
Ref: 3D-GAA21722
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |